The Obesity ETF (SLIM) Holdings & Expense Ratio

For informational purposes only. Not financial advice.

Quick Answer

The Obesity ETF (SLIM) has a 0.35% expense ratio and $12M in assets under management. Holdings and weights below are as of Mar 15, 2026.

In the stored portfolio snapshot, the largest listed holding is Novo Nordisk A/S ADR (NVO) at 19.95%, and the largest sector allocation is Healthcare at 91.9%.

The Obesity ETF (SLIM) ETF — Price, Holdings & Analysis

ETF Overview

SLIM aims to capture the performance of companies globally that are expected to benefit from the increasing prevalence of obesity. The ETF tracks the Solactive Obesity Index, investing at least 80% of its net assets in its constituent stocks. This targeted approach results in a concentrated portfolio, with a significant allocation to the healthcare sector (91.9%). The fund's top holdings include Novo Nordisk A/S ADR (19.95%), a major player in diabetes and obesity care, and DexCom Inc (13.38%), a company specializing in continuous glucose monitoring systems. Other significant holdings include Fresenius Medical Care AG & Co. KGaA (8.64%) and Insulet Corp (6.27%). SLIM offers investors a way to invest in companies involved in addressing and managing obesity and related conditions.

Risk Metrics

SLIM's non-diversified nature and concentrated sector allocation introduce specific risks. The heavy weighting in healthcare (91.9%) means the fund's performance is highly correlated with the performance of that sector. A significant portion of the fund is allocated to its top holdings, with Novo Nordisk A/S ADR comprising nearly 20% of the portfolio, indicating concentration risk. The fund's beta of 0.70 suggests it is less volatile than the overall market. The expense ratio of 0.35% will create a drag on performance over time, although this is in line with similar thematic ETFs. Investors should be aware of these factors when considering an investment in SLIM. Past performance does not guarantee future results.

Beta: 0.70

Expense Ratio

0.35%

What does SLIM hold?

Holding	Weight
Novo Nordisk A/S ADR (NVO)	19.95%
DexCom Inc (DXCM)	13.38%
Fresenius Medical Care AG & Co. KGaA (FME.DE)	8.64%
Insulet Corp (PODD)	6.27%
Tandem Diabetes Care Inc (TNDM)	4.97%
Fisher & Paykel Healthcare Corp Ltd (FPH.NZ)	4.90%
DaVita Inc (DVA)	4.55%
Abiomed Inc (ABMD)	3.83%
Herbalife Nutrition Ltd (HLF)	3.17%
iRhythm Technologies Inc (IRTC)	3.16%

Holdings and weights as of Mar 15, 2026. This fund data is more than 45 days old; verify current holdings with the issuer.

How Is the Fund Allocated?

Sector	Weight
Healthcare	91.9%
Consumer Defensive	4.3%
Consumer Cyclical	3.9%

Dividend Yield

0.57%

ARK Innovation ETF (ARKK) — 0.75% expense ratio
Invesco QQQ Trust, Series 1 (QQQ) — 0.18% expense ratio
State Street SPDR Dow Jones Industrial Average ETF Trust (DIA) — 0.16% expense ratio
State Street Energy Select Sector SPDR ETF (XLE) — 0.08% expense ratio
State Street Technology Select Sector SPDR ETF (XLK) — 0.08% expense ratio
WisdomTree Emerging Markets ESG Fund (DVEM) — 0.32% expense ratio
Goldman Sachs ActiveBeta Emerging Markets Equity ETF (GEM) — 0.59% expense ratio
iShares MSCI EAFE ETF (EFA) — 0.32% expense ratio

Questions & Answers

What is SLIM and what does it track?

The Obesity ETF (SLIM) seeks to replicate the performance of the Solactive Obesity Index. This index is designed to track companies globally that are positioned to profit from servicing the obese population.

These companies include those involved in biotechnology, pharmaceuticals, healthcare, medical devices, weight loss programs, weight loss supplements, and plus-sized apparel.

What is the expense ratio for SLIM?

The expense ratio for SLIM is 0.35%. This means that for every $10,000 invested in the fund, $35 is deducted annually to cover operating expenses.

While it's difficult to determine a precise category average for such a niche thematic ETF, the expense ratio is comparable to other specialized equity ETFs. The expense ratio as a factor impacting the overall return of the fund over time may be worth researching.

What are the top holdings in SLIM?

SLIM's top holdings reflect its focus on companies involved in obesity-related products and services.

As of 2026-03-15, the top three holdings are Novo Nordisk A/S ADR (19.95%), a leading pharmaceutical company in diabetes and obesity care; DexCom Inc (13.38%), which specializes in continuous glucose monitoring systems; and Fresenius Medical Care AG & Co.

Is SLIM a good long-term investment?

Whether SLIM is a suitable long-term investment depends on an individual's investment goals and risk tolerance. The fund offers targeted exposure to a specific theme, which can lead to concentrated risk.

SLIM's performance will be influenced by the growth of the obesity-related market and the success of its constituent companies.

How does SLIM compare to similar ETFs?

SLIM is unique in its specific focus on companies profiting from the obesity market. While there aren't many directly comparable ETFs, some broader healthcare ETFs may have overlapping holdings.

SLIM's expense ratio of 0.35% is competitive within the thematic ETF space. With AUM of $0.01 billion, SLIM is a relatively small ETF, which can impact liquidity and trading costs.

Does SLIM pay dividends?

Yes, SLIM pays dividends. The current dividend yield for SLIM is 0.57%. This means that for every $100 invested in the fund, investors can expect to receive $0.57 in dividend payments annually.

The dividend yield may fluctuate based on the performance of the underlying holdings and the fund's distribution policy.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

Written by machine, not reviewed page by page. Editorial oversight is systemic: the rules and the sources are checked, individual pages are not.